NAFLD Fibrosis Score

Test Code

NASH

Quest Code

91979

CPT Codes
82947, 84450, 84460, 85049, 82040,

Includes

Glucose, AST, ALT, Platelet Count, Albumin, Calculated Components, Personal Factors

Preferred Specimen

1 mL serum collected in a Serum Separator Tube (SST®) and 1 mL whole blood collected in an EDTA (lavender-top) tube

Patient Preparation
Fasting preferred. Fasting is defined as no consumption of food or beverage other than water for at least 8 hours before testing.

Minimum Volume

0.5 mL serum • 0.5 mL whole blood

Instructions

For risk calculations to be performed, the following patient-specific information must be provided at the time of order:
Age: Years
Gender: M (for male) or F (for female)
Height Feet: Feet
Height Inches: Inches
Weight: lbs.
Diabetes Status: Y (for yes) or N (for no)

Transport Container

Serum Separator Tube (SST®) and EDTA (lavender-top) tube

Transport Temperature

Room temperature

Specimen Stability

Serum
Room temperature: 72 hours
Refrigerated: 5 days
Frozen: Unacceptable

Whole blood
Room temperature: 48 hours
Refrigerated: Not established
Frozen: Not established

Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)

See individual tests

Methodology
Spectrophotometry (SP) • Electronic Sizing and Counting/Cytometry/Microscopy

Reference Range

See Laboratory Report

Clinical Significance

The NAFLD fibrosis score is a simple noninvasive approach to identify patients that may have significant liver fibrosis and who therefore might benefit from additional studies such as elastography or liver biopsy. Non-alcoholic fatty liver disease (NAFLD) affects approximately 30% of adults in developed countries. It is associated with obesity, diabetes, and dyslipidemia and is considered the liver manifestation of the metabolic syndrome. This disease is often asymptomatic. In some individuals, NAFLD is associated with inflammation (non-alcoholic steatohepatitis [NASH]) and may progress to liver fibrosis and ultimately to cirrhosis and attendant complications. Such individuals are also at risk for the development of hepatocellular carcinoma. In patients with NAFLD, liver fibrosis is an important prognostic factor that predicts progression and outcome. The NAFLD fibrosis score was initially published by Angulo et al. (Hepatology 45, 846 (2007)) and has since been extensively validated. The score assesses selected laboratory measures (glucose levels, platelet count, albumin, AST/ALT ratio) in combination with basic patient characteristics (age and BMI). The panel components and the NAFLD fibrosis score are recommended by professional societies including AASLD, AGA and ACG.

Performing Laboratory

Quest Diagnostics LLC

200 Forest Street, 3rd Floor, Suite B

Marlborough, MA 01752-3023

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed. Any Profile/panel component may be ordered separately. Reflex tests are performed at an additional charge.